Yes a CR would be dilutive. But look at the reward it would bring market cap wise if the trial goes to plan. This more than makes up for any dilution now. And this is only considering DMD.
This trial, when done and if sucessful, opens a non diluting funding stream into all the other indications.
So there are plenty of positives for both CR and partnership.
Company making times at the moment.
Chart, page-4335
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.9¢ | 7.9¢ | 7.6¢ | $26.62K | 343.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 113467 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 98248 | 1 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.7¢ |
Change
0.000 ( 1.28 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 7.9¢ | 7.7¢ | 14800 | ||
| Last updated 15.52pm 06/05/2024 ? | |||||
| PER (ASX) Chart |